Ondansetron dosing in pediatric gastroenteritis: A prospective cohort, dose-response study

Pediatric Drugs

Volumn 12, Issue 6, 2010, Pages 405-410

  Freedman, Stephen B ^a   Powell, Elizabeth C ^b   Nava Ocampo, Alejandro A ^a,c,d   Finkelstein, Yaron ^a,c,e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d PharmaReasons   (Canada)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Antiemetics, therapeutic use; Children; Dose response; Gastroenteritis, treatment; Ondansetron, therapeutic use

Indexed keywords

ONDANSETRON; ORAL REHYDRATION SOLUTION;

ARTICLE; CHILD; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; FEMALE; GASTROENTERITIS; HEART ARRHYTHMIA; HUMAN; INFANT; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEHYDRATION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUID THERAPY; GASTROENTERITIS; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; ONDANSETRON; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 78049372739     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11537770-000000000-00000     Document Type: Article

References (23)

1. Black RE, Morris SS, Bryce J. Where and why are 10million children dying every year? Lancet 2003; 361: 2226-34
2. King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52: 1-16
3. Forster J, Guarino A, Parez N, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years ofage. Pediatrics 2009; 123: e393-400
4. Mast TC, DeMuro-Mercon C, Kelly CM, et al. The impact of rotavirus gastroenteritis on the family. BMC Pediatrics 2009; 9: 11
5. Pascicha PJ. Prokinetic and antiemetic drugs. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. Toronto (ON): McGraw-Hill Companies, Inc., 2001: 1029-33
6. Freedman SB, Adler M, Seshadri R, et al. Oral ondansetron for gastroenteritis in a pediatric emergency department. New Engl J Med 2006; 354: 1698-705
7. Ramsook C, Sahagun-Carreon I, Kozinetz CA, et al. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med 2002; 39: 397-403
8. Reeves JJ, Shannon MW, Fleisher GR. Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial. Pedia-trics 2002; 109: e62
9. Roslund G, Hepps TS, McQuillen KK. The role oforal ondansetron in children with vomiting as a result ofacute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. Ann Emerg Med 2008; 52: 22-9
10. Stork CM, Brown KM, Reilly TH, et al. Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children. Acad Emerg Med 2006; 13: 1027-33
11. Cubeddu LX, Trujillo LM, Talmaciu I, et al. Antiemetic activity ofondansetron in acute gastroenteritis. Aliment Pharmacol Ther 1997; 11: 185-91
12. DeCamp LR, Byerley JS, Doshi N, et al. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2008; 162: 858-65
13. Manteuffel J. Use ofantiemetics in children with acute gastroenteritis: are they safe and effective? J Emerg Trauma Shock 2009; 2: 3-5
14. Levine DA. Antiemetics for acute gastroenteritis in children. Curr Opin Pediatr 2009; 21: 294-8
15. Leung AK, Robson WL. Acute gastroenteritis in children: role ofanti-emetic medication for gastroenteritis-related vomiting. Paediatr Drugs 2007; 9: 175-84
16. Sandoval C, Corbi D, Strobino B, et al. Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 1999; 17: 309-13
17. Lawhorn CD, Kymer PJ, Stewart FC, et al. Ondansetron dose response curve in high-risk pediatric patients. J Clin Anesth 1997; 9: 637-42
18. Sadhasivam S, Shende D, Madan R. Prophylactic ondansetron in prevention ofpostoperative nausea and vomiting following pediatric strabismus surgery: a dose-response study. Anesthesiology 2000; 92: 1035-42
19. Watcha MF, Bras PJ, Cieslak GD, et al. The dose-response relationship of ondansetron in preventing postoperative emesis in pediatric patients under-going ambulatory surgery. Anesthesiology 1995; 82: 47-52
20. Hasler SB, Hirt A, Ridolfi Luethy A, et al. Safety of ondansetron loadingdoses in children with cancer. Support Care Cancer 2008; 16: 469-75
21. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-47
22. Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992; 66: 192-7
23. Lajolo PP, del Giglio A. Skipping day 2 antiemetic medications may improve chemotherapy induced delayed nausea and vomiting control: results of two pilotphase II trials. Support Care Cancer 2007; 15: 343-6